DYNAMIC CHARACTERISTICS OF COAGULATION AND CONTRACTION OF PLATELET-FIBRIN CLOTS PREPARED IN THE PRESENCE OF NONSTEROIDAL AND STEROIDAL ANTI-INFLAMMATORY DRUGS

The article presents the results of a study on the effect of some steroidal and nonsteroidal anti-inflammatory drugs on the rate of formation (coagulation) and the rate of retraction (contraction) of clots prepared from erythrocyte-free plasma enriched with platelets. It was found that high concentrations of anti-inflammatory drugs of these groups, through selective effects on platelet metabolism, change the rate and intensity of coagulation and clot contractionin different ways. The nonsteroidal anti-inflammatory drug meloxicam does not change the time of clot formation (coagulation), but significantly accelerates its contraction. It is suggested that the acceleration of the onset and complete completion of contraction is due to the fact that meloxicam suppresses platelet cyclooxygenase of the second type. As a result, platelets stop producing prostacyclin, which is an antagonist of the platelet activator thromboxane-A2. Another nonsteroidal antiinflammatory drug ketorol, on the contrary, significantly prolongs the onset of coagulation of the clot and completely suppresses its contraction. This is due to the fact that this drug is a strong inhibitor of cyclooxygenase of the first type. Accordingly, the platelet activator trom-boxan-A2, which is dependent on this enzyme, ceases to be synthesized. The steroidal anti-inflammatory drug dexamethasone, in comparison with the control, slightly accelerates both the time of onset of coagulation and the time of onset of clot contraception. However, this effect has low statistical validity. The results obtained are indirect evidence that meloxicam and dexamethasone do not prevent platelet activation. And, therefore, they can be used in parallel with the treatment of platelet-rich plasma. Ketorolac, on the contrary, suppresses platelet activation. And, consequently, its use in parallel with platelet plasma treatment can reduce its therapeutic regenerative effect.

1. Yushkov, B.G. Platelets and regeneration / Yushkov B.G. // Bulletin of Siberian medicine. – 2021 – №20 (2). – Pp. 216-227.

2. The effect of cell-free and platelet-free plasma on the healing of a burn wound in rats / Sverdlova M.V., Stekolnikov A.A., Minina A.O., Bokarev A.V. // International Bulletin of Veterinary Medicine. - 2022. - No. 2. - pp. 188-194.

3. Autologous Platelet-Rich Plasma Preparations: Influence of Nonsteroidal Antiinflammatory Drugs on Platelet Function / Schippinger G., Prüller F., Divjak M., e.t.c. // The Orthopaedic Journal of Sports Medicine. – 2015. - Jun 23;3(6). – 2325967115588896.

4. Cyclooxygenases and platelet functions / Bruno A., Tacconelli S., Contursi A., e.t.c. // Adv Pharmacol. – 2023. - № 97. – P. 133-165.

5. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition / Brenneis C., Maier T.J., Schmidt R., e.t.c. // The FASEB Journal. – 2006. - Jul;20(9). – P. 1352-60.

6. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance / Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., Schrör K. // The Lancet. Research Letters. 1999. - March 13 - V.353. – P. 900-901.

7. The effect of local antiseptics and antiinflammatory drugs on the functional activity of platelet-rich plasma in the complex therapy of periodontitis / Orekhova L.Yu., Kudryavtseva T.V., Vavilova T.V., Tachalov V.V. // Periodontology. - 2008. - № 1 (46). - Pp. 61-64.

8. The effect of nonsteroidal and steroid antiinflammatory drugs on platelet activation IN VITRO / Bokarev A.V., Minina A.O., Gorokhov V.E. // International Bulletin of Veterinary Medicine. - 2023. - No. 4. - pp. 463-472.

9. Dependence of clot contraction (retraction) on the molecular and cellular composition of blood / Peshkova A.D., Lozhkin A.P., Fakhtullina L.S., et al. // Kazan Medical Journal. – 2016. - Volume 97, No. 1. – pp. 70-77.

10. Patent No. 2789518 Russian Federation, IPC A61K 35/19, A61K 35/16, G01N 33/49. A method for obtaining platelet–enriched plasma from small volumes of blood: No. 2022113042: application 13.05.2022: publ. 06.02.2023 / Stekolnikov A.A., Bokarev A.V., Gorokhov V.E., Minina A.O., Sverdlova M.V., Zakharov A.Yu. - 5 p.

11. Patrono, C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective / Patrono C. // Br J Clin Pharmacol. – 2016. - Oct; 82(4). – P. 957–964.

12. A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets / Hu Q., Cho M.S., Thiagarajan P.T., e.t.c. // Platelets. - 2017 - Jan;28(1). P. 99-102.

13. Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice / Barbieri S.S., Petrucci G., Tarantino E., e.t.c. // Thrombosis and Haemostasis/ - 2015. - Nov 25;114(6). – P. 1218-29.

14. Virtual lack of annexins in human platelets argues against a role in phospholipase A2 regulation and platelet secrecy / Ferrieres J., Simon M.F., Fauvel J., Chap H // J Lipid Mediat Cell Signal. – 1994. - Mar;9(2). pp. 155-65.

15. Ligand-specific glucocorticoid receptor activation in human platelets / Moraes L.A., Paul-Clark M.J., Rickman A., e.t.c. // Blood. – 2005. – Dec; 106(13). – P. 4167-75.